All News
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.
Read Article
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
Read Article
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
Predictors of Adverse Pregnancy Outcomes in Lupus
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
Read Article
Mucosal Disruptions as Initiators of Rheumatoid Arthritis
Many have suggested that microbiome and mucosal disruptions are contributors to autoimmunity, especially rheumatoid arthritis (RA). This is partly represented in what is known as the "mucosal hypothesis" to RA. A current review article by Hollers, et al. addresses how distinct mucosal endotypes can serve as drivers or initiators of RA.
Read Article
Analgesic Prescribing in Patients with Inflammatory Arthritis
A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis (IA) patients has declined, but still remains substantial, including opioid prescribing.
Stop Counting Bugs (10.4.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.
Read Article
2023 EULAR Recommendations on Management of Fatigue
A 2023 EULAR task force has made recommendations to the approach and management of fatigue in patients with inflammatory rheumatic and musculoskeletal diseases (I-RMDs).
ASAS Imaging Recommendations for Suspected Spondyloarthritis
ASAS (Assessment of Spondyloarthritis International Society) has convened specialized task force to guide imaging request on patients with suspected/known axial spondyloarthritis (axSpA).
Read Article
Which One is the Loneliest Number (9.27.2024)
Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.
Read Article
Stratified Cancer Screening in Dermatomyositis
The International Myositis Assessment and Clinical Studies Group (IMACS) have published evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.
Read Article
INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis
The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.
Read Article
